

Supplementary Table 2. Characteristics of patients in included studies

| Study | Stroke (%) | Age (yr) | Male (%) | HTN (%) | DM (%) | CHF (%) | VD (%) | HLP (%) | Previous stroke (%) | CHADS ₂ score | CHA ₂ DS ₂ -VASc score | Asymptomatic (%) | Lost to follow-up (%) |
|--|------------|------------|----------|---------|--------|---------|--------|---------|---------------------|--------------------------|--|------------------|-----------------------|
| Asaithambi et al. (2017) ^{19*} | NA | NA | NA | 76 | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Carrasco et al. (2018) ²⁰ | 100 | 66 | 47 | 78 | 27 | 4 | NA | 68 | 15 | NA | NA | NA | NA |
| Ching et al. (2018) ^{21*} | 100 | 70 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Cotter et al. (2013) ²² | 100 | 51±14 | 54.9 | NA | NA | NA | NA | NA | NA | 2 (2–3) | 3 (2–4) | 92 | 0 |
| CRYSTAL-AF (2014) ²³ | 90.5 | 62±11 | 64.3 | 65.2 | 15.4 | NA | NA | 56.6 | 16.7 | 3 (2–4) | NA | 79 | 5.4 |
| CRYSTAL-AF (2017) ^{24*} | 100 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| de Lera et al. (2016) ^{25*} | 100 | 67 | 55 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Dion et al. (2010) ²⁶ | 100 | 49±14 | 62.5 | 29.2 | 0 | NA | NA | 33.3 | NA | NA | NA | 100 | 0 |
| Etgen et al. (2013) ²⁷ | 100 | 61.6 | 50 | 63.6 | 9.1 | NA | NA | 72.7 | NA | NA | NA | 67 | 0 |
| Israel et al. (2017) ²⁸ | 100 | 65±9 | 61.1 | 82.9 | 24.4 | NA | 33.3 | NA | NA | NA | 4.5±1.3 | NA | 0 |
| Jorfida et al. (2016) ²⁹ | 100 | 68±9 | 57.4 | 88.7 | 18.5 | NA | NA | NA | 27.8 | 3.4±0.8 | 4.5±1.2 | 76 | 0 |
| Kamel et al. (2018) ^{30*} | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Katz et al. (2017) ^{31*} | NA | 65 | 68.1 | NA | NA | NA | NA | NA | NA | 3.5 | 4.5 | NA | NA |
| Kotlarz-Böttcher et al. (2018) ^{32*} | 100 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Makimoto et al. (2017) ³³ | 100 | 62±12 | 58 | 73 | 16 | NA | 12 | NA | NA | NA | 4.1±1.3 | NA | 0 |
| Navarro Pérez et al. (2018) ^{34*} | NA | 74.4 | 56.8 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Noone et al. (2016) ^{35*} | 100 | NA | NA | 41.7 | 7.5 | NA | 23.6 | 74.8 | 56.3 | NA | NA | NA | NA |
| Pallesen et al. (2017) ^{36*} | 100 | 61 | 64 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Poli et al. (2016) ³⁷ | 89 | 66±12 | 47 | 79 | 15 | NA | 36 | NA | NA | NA | 5 (4–6) | 92 | 0 |
| REVEAL-AF (2018) ^{38*} | 100 | - | - | - | - | - | - | - | - | - | - | - | - |
| Ritter et al. (2013) ³⁹ | 100 | 63 (48–72) | 57 | 70 | 11.6 | 0 | 13.3 | NA | NA | 3 (2–3) | 4 (3–5) | NA | 1.6 |
| Rodríguez-Campello et al. (2015) ^{40*} | 100 | 75±9 | 60.7 | 64.3 | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Rojo-Martinez et al. (2013) ⁴¹ | 90.1 | 67±13 | 46.5 | 55.4 | 19.8 | NA | 20.9 | 52.5 | NA | NA | 4.51±1.54 | NA | NA |
| Sethi et al. (2017) ^{42*} | 100 | 67.9 | 53.6 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| SPIDER Registry (2015) ^{43*} | NA | 67±13 | 59.4 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| SURPRISE (2014) ⁴⁴ | 72.3 | 57 | 55.1 | 45.3 | 6.9 | NA | NA | NA | NA | 2 | 3 | 100 | 8.4 |
| TRACK-AF (2018) ⁴⁵ | 81.9 | 64±13 | 56.2 | NA | NA | NA | NA | NA | NA | NA | 4 (3–6) | NA | 0 |
| Ziegler et al. (2015) ⁴⁶ (2017) ⁴⁷ | NA | 65±13 | 53 | NA | NA | NA | NA | NA | NA | NA | NA | NA | 0 |

Values are presented as mean±standard deviation or median (interquartile range).

HTN, hypertension; DM, diabetes mellitus; CHF, congestive heart failure; VD, vascular disease; HLP, hyperlipidemia; NA, not available; CRYSTAL-AF, Cryptogenic Stroke and underlying Atrial Fibrillation; REVEAL AF, Incidence of AF in High Risk Patients; SPIDER Registry, Stroke Prevention through the Improved Detection of AF registry; SURPRISE, Stroke Prior to Diagnosis of Atrial Fibrillation Using Long-term Observation with Implantable Cardiac Monitoring Apparatus Reveal; TRACK-AF, Follow-up of Kryptogenic Stroke Patients With Implantable vs. Non-invasive Devices to Detect Atrial Fibrillation.

*Available only as abstracts.